The safety profile of anti‐tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient‐years follow‐up

Abstract

Serious infections, malignancies and neurological disease complicate anti-TNF use in clinical practice. Although evidence for causality is unclear, potential mechanisms and predisposing factors need to be explored. In individual patients, the risk/benefit analysis needs to be carefully assessed and discussed prior to commencement of therapy.